References
- Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol.5(11), 655–663 (2004).
- Mikal S, Campbell AJ. Carcinoma of the pancreas; diagnostic and operative criteria based on 100 consecutive autopsies. Surgery28(6), 963–969 (1950).
- Mandala M, Reni M, Cascinu S et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann. Oncol.18(10), 1660–1665 (2007).
- Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med.343(25), 1846–1850 (2000).
- Mandala M, Tondini C. The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. Expert Rev. Anticancer Ther.11(4), 579–588 (2011).
- Epstein AS, Soff GA, Capanu M et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer doi:10.1002/cncr.26600 (2011) (Epub ahead of print).
- Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA98(6), 3352–3357 (2001).
- Altinbas M, Coskun HS, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost.2(8), 1266–1271 (2004).
- Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol.22(10), 1944–1948 (2004).
- Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol.23(10), 2130–2135 (2005).
- Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349(2), 146–153 (2003).
- Kuderer N, Ortel T, Khorana A, Francis C, Lyman G. Low molecular weight heparin thromboprophylaxis in ambulatory cancer patients: a systematic review and meta-analysis of randomized controlled trials. Blood (ASH Proc.)114 (2009) (Abstract 490).
- Maraveyas A, Waters J, Roy R. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised Phase IIB trial (the UK FRAGEM study). Eur. J. Cancer Suppl.7, 362 (2009).
- Riess H, Pelzer U, Deutschinoff G et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial. J. Clin. Oncol. (ASCO Proc.)27(Suppl. 18), (2009) (Abstract LBA4506).
- Agnelli G, George G, Fisher W et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. J. Clin. Oncol. (ASCO Proc.)29 (2011) (Abstract LBA 4506).
- Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu. Rev. Med.62, 41–57 (2011).
Website
- ClinicalTrials.gov. http://clinicaltrials.gov